Luye Pharma Group Ltd.
Symbol: 2186.HK
HKSE
3.02
HKDMarktpreis heute
19.0836
P/E-Verhältnis
1.7261
PEG-Verhältnis
11.36B
MRK Kapital
- 0.00%
DIV Rendite
Luye Pharma Group Ltd. (2186-HK) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 30442.4 | 8522.3 | 5544.3 | 5510.3 | ||||||||||||||||||||
balance-sheet.row.short-term-investments | 8899.94 | 2867.5 | 3220.5 | 3072.1 | ||||||||||||||||||||
balance-sheet.row.net-receivables | 9083.1 | 2354.9 | 1783.7 | 1765.1 | ||||||||||||||||||||
balance-sheet.row.inventory | 3262.94 | 827.9 | 772.9 | 746.3 | ||||||||||||||||||||
balance-sheet.row.other-current-assets | 14658.34 | 3009.9 | 4658.7 | 5059.1 | ||||||||||||||||||||
balance-sheet.row.total-current-assets | 47624.65 | 10703.3 | 10785.8 | 10396.7 | ||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 19926.44 | 5127.2 | 4909.1 | 4594.5 | ||||||||||||||||||||
balance-sheet.row.goodwill | 4170.88 | 1041.9 | 1003.4 | 985.4 | ||||||||||||||||||||
balance-sheet.row.intangible-assets | 25053.85 | 6317.9 | 5984.7 | 5441.8 | ||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 29224.74 | 7359.8 | 6988.1 | 6427.2 | ||||||||||||||||||||
balance-sheet.row.long-term-investments | 1699.95 | 1968.4 | -2106.4 | -2489.9 | ||||||||||||||||||||
balance-sheet.row.tax-assets | 291.01 | 144.6 | 113.9 | 133.1 | ||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 4815.04 | 187.4 | 3559.1 | 3520.4 | ||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 55957.17 | 14787.4 | 13463.8 | 12185.4 | ||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-assets | 103581.81 | 25490.7 | 24249.6 | 22582.1 | ||||||||||||||||||||
balance-sheet.row.account-payables | 2864.67 | 767.2 | 559.9 | 570.9 | ||||||||||||||||||||
balance-sheet.row.short-term-debt | 25899.19 | 5195.8 | 6839.8 | 5263.2 | ||||||||||||||||||||
balance-sheet.row.tax-payables | 565.73 | 294.9 | 256.3 | 205.1 | ||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 10671.39 | 3228.2 | 2264.7 | 4227.6 | ||||||||||||||||||||
Deferred Revenue Non Current | 264.72 | 103.6 | 175 | 209.4 | ||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 94.99 | - | - | - | ||||||||||||||||||||
balance-sheet.row.other-current-liab | 10345.67 | 2193.4 | 2087.5 | 1496.1 | ||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 13045.19 | 3824.4 | 3720.7 | 6138 | ||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 223.17 | 70.6 | 38.5 | 42 | ||||||||||||||||||||
balance-sheet.row.total-liab | 52136.22 | 11962.2 | 13207.9 | 13468.2 | ||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.common-stock | 1944.43 | 486.1 | 457 | 455.8 | ||||||||||||||||||||
balance-sheet.row.retained-earnings | 14005.23 | 0 | 6667.3 | 6061.8 | ||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 16081.52 | 7885.8 | 254.5 | 534 | ||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 15700.8 | 4159.3 | 2797.3 | 1436.4 | ||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 47731.99 | 12531.2 | 10176 | 8488.1 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 103581.81 | 25490.7 | 24249.6 | 22582.1 | ||||||||||||||||||||
balance-sheet.row.minority-interest | 3713.61 | 997.3 | 865.8 | 625.8 | ||||||||||||||||||||
balance-sheet.row.total-equity | 51445.6 | 13528.5 | 11041.7 | 9113.9 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 103581.81 | - | - | - | ||||||||||||||||||||
Total Investments | 7732.43 | 1968.4 | 1114.1 | 582.2 | ||||||||||||||||||||
balance-sheet.row.total-debt | 36570.58 | 8423.9 | 9104.5 | 9490.8 | ||||||||||||||||||||
balance-sheet.row.net-debt | 18731.27 | 2769.1 | 6780.8 | 7052.5 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 532.61 | 669.8 | -74.6 | 942.2 | |||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 331.43 | 671.3 | 582 | 510.9 | |||||||||||||||||||
cash-flows.row.deferred-income-tax | -914.59 | 0 | -311.9 | -505.9 | |||||||||||||||||||
cash-flows.row.stock-based-compensation | 20.64 | 25.4 | 50 | 50.9 | |||||||||||||||||||
cash-flows.row.change-in-working-capital | 186.15 | 319.8 | -418.1 | -300.3 | |||||||||||||||||||
cash-flows.row.account-receivables | -403.05 | -18.8 | -211.8 | 145 | |||||||||||||||||||
cash-flows.row.inventory | -30.67 | -26.6 | -134 | 4.9 | |||||||||||||||||||
cash-flows.row.account-payables | 118.98 | 18.8 | 211.8 | -145 | |||||||||||||||||||
cash-flows.row.other-working-capital | 619.86 | 346.4 | -284 | -305.2 | |||||||||||||||||||
cash-flows.row.other-non-cash-items | -381.1 | -32.5 | 355 | 335.7 | |||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 689.73 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -544.22 | -1163.7 | -1541.6 | -1519.9 | |||||||||||||||||||
cash-flows.row.acquisitions-net | 0.11 | 0 | -808.5 | -450.8 | |||||||||||||||||||
cash-flows.row.purchases-of-investments | -218.72 | -3485.9 | -3975.7 | -2859.2 | |||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 627.68 | 2899.5 | 1919 | 4153.8 | |||||||||||||||||||
cash-flows.row.other-investing-activites | -78.02 | 91.8 | 970.7 | 814.2 | |||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -78.02 | -1658.3 | -3436 | 138.2 | |||||||||||||||||||
cash-flows.row.debt-repayment | -561.84 | -8301.9 | -7536.7 | -5896.7 | |||||||||||||||||||
cash-flows.row.common-stock-issued | 1043.83 | 189.2 | 1044.5 | 7326.7 | |||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | -78 | |||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | -175.5 | |||||||||||||||||||
cash-flows.row.other-financing-activites | 1522.95 | 8166.9 | 8371.1 | -922.6 | |||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 1522.95 | 54.1 | 1878.9 | 254 | |||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 14.37 | -164.1 | -52.4 | 112.4 | |||||||||||||||||||
cash-flows.row.net-change-in-cash | 3254.94 | -114.5 | -1427.1 | 1538 | |||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 5899.82 | 2323.7 | 2438.3 | 3865.4 | |||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 2644.89 | 2438.3 | 3865.4 | 2327.3 | |||||||||||||||||||
cash-flows.row.operating-cash-flow | 689.73 | 1653.8 | 182.4 | 1033.4 | |||||||||||||||||||
cash-flows.row.capital-expenditure | -544.22 | -1163.7 | -1541.6 | -1519.9 | |||||||||||||||||||
cash-flows.row.free-cash-flow | 145.51 | 490.1 | -1359.2 | -486.4 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 6143.08 | 6143.1 | 5981.7 | 5200.2 | ||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 1938.9 | 1938.9 | 1841.1 | 1803.5 | ||||||||||||||||||||
income-statement-row.row.gross-profit | 4204.18 | 4204.2 | 4140.5 | 3396.7 | ||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.research-development | 586.16 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 643.97 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 2056.17 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0.3 | -73.3 | 155.2 | ||||||||||||||||||||
income-statement-row.row.operating-expenses | 3038.59 | 3175.4 | 3186.6 | 3113.9 | ||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 4977.49 | 5114.4 | 5027.8 | 4917.4 | ||||||||||||||||||||
income-statement-row.row.interest-income | 465.49 | 117.1 | 88.7 | 102 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 347.02 | 675.5 | 471.8 | 399.5 | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 2056.17 | - | - | - | ||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -187.34 | -187.3 | -545.2 | -461.5 | ||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0.3 | -73.3 | 155.2 | ||||||||||||||||||||
income-statement-row.row.total-operating-expenses | -187.34 | -187.3 | -545.2 | -461.5 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 347.02 | 675.5 | 471.8 | 399.5 | ||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 634.89 | 701.9 | 671.3 | 582 | ||||||||||||||||||||
income-statement-row.row.ebitda-caps | 1522.33 | - | - | - | ||||||||||||||||||||
income-statement-row.row.operating-income | 887.44 | 887.4 | 1215 | 387 | ||||||||||||||||||||
income-statement-row.row.income-before-tax | 700.1 | 700.1 | 669.8 | -74.6 | ||||||||||||||||||||
income-statement-row.row.income-tax-expense | 161.02 | 161 | 86.5 | 70.2 | ||||||||||||||||||||
income-statement-row.row.net-income | 532.61 | 532.6 | 604.8 | -144.8 |
Häufig gestellte Frage
Wie hoch ist die Luye Pharma Group Ltd. (2186.HK) Gesamtvermögen?
Luye Pharma Group Ltd. (2186.HK) Gesamtvermögen ist 25490715000.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist 3238970000.000.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 0.684.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist 0.039.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist 0.087.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist 0.144.
Was ist der Luye Pharma Group Ltd. (2186.HK) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist 532605000.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 8423947000.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 3175450000.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist 5654804000.000.